Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future by Harriet Lampe, Laura Tam, Aaron R. Hansen

Get full text

The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience by Esmail Al-Ezzi, Abhenil Mittal, Zachary W. Veitch, Amer Zahralliyali, Nely Mercy Diaz Mejia, Osama Abdeljalil, Husam Alqaisi, Vikaash Kumar, Aaron R. Hansen, Nazanin Fallah-Rad, Srikala S. Sridhar

Get full text

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial by Alberto Hernando‐Calvo, Eoghan Malone, Daphne Day, Amy Prawira, Ilan Weinreb, S. Y. Cindy Yang, Horace Wong, Angela Rodriguez, Sarah Jennings, Anneli Eliason, Lisa Wang, Anna Spreafico, Lillian L. Siu, Aaron R. Hansen

Get full text

Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensi... by Wei Xu, Ilan Weinreb, John R de Almeida, Christopher W Noel, Maria Veigas, Rosemary Martino, Douglas B Chepeha, Scott V Bratman, David P Goldstein, Aaron R Hansen, Eugene Yu, Ur Metser, Bayardo Perez-Ordonez, John Kim

Get full text

The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey by Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulières, Sebastien J. Hotte, Di Maria Jiang

Get full text

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development by Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul

Get full text

Out‐of‐pocket costs associated with head and neck cancer treatment by Mohemmed N. Khan, Katrina Hueniken, Mirko Manojlovic‐Kolarski, Lawson Eng, Maryam Mirshams, Khaleeq Khan, Colleen Simpson, Michael Au, Geoffrey Liu, Wei Xu, Christopher J. Longo, David P. Goldstein, Jolie Ringash, Rosemary Martino, Aaron R. Hansen, John R. deAlmeida

Get full text

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study by Kari Ala‐Leppilampi, Natalie A. Baker, Chris McKillop, Marcus O. Butler, Lillian L. Siu, Anna Spreafico, Albiruni R. Abdul Razak, Anthony M. Joshua, David Hogg, Philippe L. Bedard, Natasha Leighl, Amit M. Oza, Janet A. Parsons, Aaron R. Hansen

Get full text

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma by Ambica Parmar, Sunita Ghosh, Arjun Sahgal, Aly‐Khan A. Lalani, Aaron R. Hansen, M. Neil Reaume, Lori Wood, Naveen S. Basappa, Daniel Y. C. Heng, Jeffrey Graham, Christian Kollmannsberger, Denis Soulières, Rodney H. Breau, Simon Tanguay, Anil Kapoor, Frédéric Pouliot, Georg A. Bjarnason

Get full text

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT) by Sofia Genta, Katherine Lajkosz, Noelle R. Yee, Pavlina Spiliopoulou, Alya Heirali, Aaron R. Hansen, Lillian L. Siu, Sam Saibil, Lee-Anne Stayner, Maryia Yanekina, Maxwell B. Sauder, Sareh Keshavarzi, Abdulazeez Salawu, Olga Vornicova, Marcus O. Butler, Philippe L. Bedard, Albiruni R. Abdul Razak, Robert Rottapel, Andrzej Chruscinski, Bryan Coburn, Anna Spreafico

Get full text

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort o... by Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner

Get full text

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors by Neda Stjepanovic, Amit M Oza, Anna Spreafico, Stephanie Lheureux, Marcus O Butler, Pamela S Ohashi, Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Dave Cescon, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Lillian L Siu, Daniel D De Carvalho

Get full text

Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable by Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, Ethan Basch, Jill Bell, Vishal Bhatnagar, David Cella, Philip Collis, Amylou C. Dueck, Alexandra Gilbert, Ari Gnanasakthy, Alastair Greystoke, Aaron R. Hansen, Paul Kamudoni, Olga Kholmanskikh, Bellinda L. King-Kallimanis, Harlan Krumholz, Anna Minchom, Daniel O'Connor, Joan Petrie, Claire Piccinin, Khadija Rerhou Rantell, Saaeha Rauz, Ameeta Retzer, Steven Rizk, Lynne Wagner, Maxime Sasseville, Lesley K. Seymour, Harald A. Weber, Roger Wilson, Melanie Calvert, John Devin Peipert

Get full text

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies by John Hilton, Karen Gelmon, Philippe L. Bedard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek Jonker, Aaron R. Hansen, Zachary W. Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu Chen, Deb Kellar, Irene Li, Sung-Eun Lee, Takako Kono, Brian Y. C. Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria-Bretones, Eric Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparicio, David W. Cescon

Get full text

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

Get full text